MHRA to Resume On-Site Inspections in September 2020
The UK's MHRA will resume on-site risk based GxP inspections from September 2020.
The Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom has announced it will resume on-site risk-based good practice (GxP) inspections in September 2020.
According to an August 11, 2020 press release, the agency specified that the inspection program will resume in September 2020 in line with a reduction in COVID-19 restrictions, and a scale-up to a full program of inspections is expected in October 2020. On-site inspections were suspended on March 20, 2020 as a result of COVID-19 social distancing and travel restriction requirements.
A combination of remote and on-site inspection approaches will be employed as COVID-19 restrictions are continuing to be eased, the agency stated in the press release. Guidance on what companies should expect in the event of an on-site inspection are available on the MHRA’s website. Any site/organization to be inspected will receive a minimum of 14 days prior notification so that planning to minimize COVID-19 risk can be performed.
Source: MHRA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
